|
Multi-element blood processing processor with successively centred chambers Group of inventions relates to medical equipment. A device contains a centrifuge, a rotor, adapted for rotation around the rotation axis, a separating cell on the rotor, which is adapted for the reception of a separating bag, which contains a blood volume. The separating bag has connection with a set of bags. The set contains a bag for components and an auxiliary bag. The separating cell is located radially outside of the rotation axis in the area with the great centrifugal force. A cavity on the rotor for the placement of the bag for the components is located radially outside of the rotation axis and radially inside from the separating cell in the area with the intermediate centrifugal force. A set of valves is adapted for interaction with tubes, which connect the bags. A hollow on the rotor for the auxiliary bag is located radially outside from the rotation axis and radially inside relative to the cavity in the area with the low centrifugal force relative to the cavity position. A method of the device application is disclosed. |
|
Group of inventions refers to medicine. A device comprises an individual blood sampler, an analyser for determining and presenting the blood characteristics in the form a blood analysis result, an execution unit connected to the individually backward feeder and configured to transfer a substance to the individual through the backward feeder. The execution unit comprises a container unit accumulating the substances. The container unit is provided together with a dosage package, which takes the blood analysis results into account to select the substances or to prepare a mixture thereof. The device also accommodates an assessment and control unit configured to share information with the analysis unit and the dosage package, and to generate control signals to control the dosage package. When implementing the method, individual's blood is sampled and analysed. Taking into account the blood analysis result and assessment criteria, the substances or mixture thereof are typed and quantified. The dosed substances or mixture thereof are mixed to the sampled blood to produce the modified blood, which is used for reperfusion into the individual or used as a perfusion solution instead of the sampled blood for a reperfusion into the individual. |
|
Pressure control in fluid container Group of inventions refers to medical equipment. A fluid container for blood processing system comprises a container body forming a container structure and having a fluid path at least partially extending through the body. The fluid path is configured to provide the fluid flow through the body. A rigid structure forms a cavity being in fluid connection with the fluid path. The rigid structure has an interface for coupling to a pressure control device and measuring a pressure in the fluid path by the pressure control device. The cavity is configured to retain an air volume between the fluid path and the interface when the fluid passes through the body. There are disclosed method for pressure control in the fluid container for the blood processing system, and a pressure control system used in the blood processing system. |
|
Centrifuge of a blood component separator comprises a body, a centrifuge actuator, a rotary table for attaching a detachable container and a cuff connecting the rotary table and an output actuator shaft of the centrifuge. The cuff comprises a reduction sleeve rigidly attached to the output actuator shaft of the centrifuge and having a bearing collar at the bottom of the sleeve for fixing an axial position of the rotary table, a many-sided tip for torque transmission onto the rotary table and a thread at the top of a sleeve port, a washer enveloping the cuff tip and rigidly fixed on a seat of the rotary table, and a locking element presented in the form of a screw with the flat clamping surface interacting the washer surface. |
|
Device comprises a cylindrical body, the first nozzle having the first blood passage, the second nozzle having the second blood passage, an adsorbent carrier, the first end plate, the second end plate and a holed blood tube, wherein: one end of the blood tube is connected to the first blood passage, while the other end is closed; the first end plate is mounted so that its outer peripheral surface contacts tightly with an inner peripheral surface of the cylindrical body; the outer peripheral surface of the second end plate and the inner peripheral surface of the cylindrical body are gapped; an outer diameter of the blood tube in the cross section perpendicular to the long direction, D1, is related to an inner diameter of the cylindrical body in the cross section perpendicular to the long direction, D2, as 0.35-0.50; the blood amount makes 6-10 ml. |
|
Method involves oxidation of 2 litres of blood with 0.06% sodium hypochlorite at 2-2.5 ml/min, and blood flow velocity 40-50 ml/min. The patient's blood is oxidised with 0.06% sodium hypochlorite in an extracorporeal venous circuit in a total dose of 0.75 mg/kg, and can be used in the patients suffering degree 1 endotoxicosis. |
|
Method of treatment of animals with surgical sepsis Kobaktan is administered intramuscularly at a dose of 2 ml per 50 kg of body weight daily for 7 days, glutoxim is administered subcutaneously at a dose of 3 mg per 1 kg of body weight once in 2 days in an amount of 10 injections, and also 1-3 sessions of hemosorption is carried out with the interval of 24-48 hours. |
|
|
Method for donor blood sampling Invention refers to medicine. For the purpose of blood banking, a donor blood dose is taken by weight or by volume into a blood container with a preservative solution with mixing the blood simultaneously with the preservative solution in the blood container. The blood sampling is combined with blood cooling to a specified temperature for a period of time not exceeding 12 minutes. |
|
Method for preparing platelet-rich plasma to be used as ingredient of ointment Invention refers to medicine, namely to an efferent therapy and traumatology, and can be used where it is necessary to stimulate a bone regeneration. That is ensured by blood sampling and stabilising in 3.8% sodium citrate. The blood is centrifuged at 1000-1500 rpm (about 300 g) for 5-7 min. After a platelet count has been measured, the plasma is lyophilised. A lyophilisate is introduced as an ingredient of an ointment in ratio to provide the final platelet concentration 800×109/l or more. The prepared ointment is applied on a body surface in a projection of a regeneration region. |
|
Method for prevention and treatment of renal graft rejection Invention refers to medicine, namely transplantology, and can be used for prevention and treatment of a renal graft rejection. That is ensured by an extracorporeal photophoresis by administering a photosentiser, recovery of a mononuclear cell concentrate, dilution in normal saline and suspension exposure to ultraviolet light Additionally, the ultraviolet exposure is followed by normal saline substitution by blood plasma in the same amount. Then, the prepared mixture is added with cytokine, granulocyte-macrophage colony-stimulating factor in a dose of 80-120 ng/ml. Thereafter, the prepared composition is incubated for 90-120 minutes. Then, plasma with cytokine is substituted by normal saline in the same amount, and the prepared suspension is then injected back into blood channels. A first photophoresis session is performed on the 3rd-4th day following the renal transplantation. The first two weeks provide performing two sessions a week. For the next six weeks, one session a week is performed. For the following third month, two sessions are performed. That is followed by one session a month for the fourth, fifth and sixth months. The therapeutic course makes 15 sessions. |
|
|
Method of treating chronic bronchitis in patients with accompanying secondary immunodeficiency Invention refers to medicine, namely to pulmonology and may be used in treating the patients with chronic bronchitis in combination with secondary immunodeficiency. For this purpose, the patient with the remitting disease undergoes 6 procedures of ozone therapy every second days by the intravenous introduction of ozonised physiological saline with the ozone concentration 600 mcg/l in the ozone-oxygen gas mixture. One week after the ozone therapy, patient's venous blood is sampled and exposed to UV light for 2 procedures every 7 days. At the first procedure, the blood volume to be exposed makes 0.8 ml/kg of patient's body weight, and at the second procedure - 1 ml/kg. |
|
|
Method of conservative treatment of shoulder epicondylitis Invention relates to medicine, namely, to traumatology and orthopedics, and can be applied in conservative treatment of shoulder epicondylitis. For this purpose rich of platelets autoplasma, obtained 1-2 hours before procedure, which contains from 725 to 3029 thousand/mcl platelets, is introduced into the point of maximal painfulness of epicondyle and in tissues located near it. Plasma is activated by 0.25% solution of CaCl2 in ratio 2:1 with addition of 5% sodium hydrocarbonate in ratio 1:20. Introduction is realised in amount from 3 to 5 ml. |
|
|
Group of inventions refers to medicine, namely to efferent therapy, and may be used for carrying out the plasmapheresis procedures. What is presented is a device consisting of a blood sampling and return unit, a blood exfusion line, a blood re-infusion line, an anticoagulant and diluent feed line, a plasma bleed line, a pressure measurement line. Return valves are provided in the blood exfusion and re-infusion lines, anticoagulant and diluent feed line, and plasma bleed line. The first return valve is fixed either in a tube of the blood exfusion line or in an input fitting of a pump segment. The second return valve is fixed either in a tube the blood re-infusion line or in an output fitting of the pump segment. The third, fourth and fifth ones accompany tubes of the anticoagulant and diluent feed line and bleed plasma line. The anticoagulant feed line and blood exfusion line are coupled in front of the first return valve or thereafter. The diluent feed line is coupled with the blood exfusion line in front of the first return valve or thereafter or coupled with the blood re-infusion line in front of the second return valve or thereafter A pump segment chamber made of an elastic material is provided between a fixed and movable plate coupled with a mechanism of its reciprocation limited by stop pieces with integrated pump level and empty sensors. The chamber fill-in volume preferentially falls within the range of 2 to 20 ml. When extended, the chamber negative pressure makes 50 to 150 mm Hg. The movable plate has the variation along the thickness, while a motion mechanism of the movable plate is electrically connected to the pressure sensor, as well as to the pump level and empty sensors. Some tubes of the anticoagulant and/or diluent feed lines fall down in case of pressure drop and movable through an external pinch tube valve or a slot unit with the variation along slot width which specifies a dose ratio of anticoagulant/blood and/or diluent/blood in the range preferentially from 1:4 to 1:48. A pressure propagation line extends through the external pinch tube valve which is electrically connected to the pump level and empty sensors. What is presented is a plasmapheresis procedure in a single-needle extracorporeal circuit involving the stage of blood exfusion and the stage of blood re-infusion. A portion of blood, a dose of the anticoagulant and/or diluent are introduced into the pump segment chamber pre-compressed at the stage of re-infusion. The exfusate volume is specified with limiting a degree of extension of the pump segment chamber. A dose of the anticoagulant and/or diluent is administered uniformly for the entire stage of exfusion in equal portions from the desired containers, or introduced immediately for the entire stage or a part thereof as a one portion from falling down volume-adjustable tanks. In the beginning of the stage of re-infusion, anticoagulant and/or diluent are blocked from backflow into the falling down tanks and/or their container, while exfusate and plasma are blocked from backflow into vein and plasmofilter, respectively. Plasma is separated at constant plasmofilter inlet pressure with the pressure level maintained by adjusting a compression speed of the pump segment chamber by means of a feedback signal supplied from the pressure measurement line in front of the plasmafilter, blocked at the stage of exfusion and opened at the stage of reinfusion. Before the end of the stage of reinfusion, at the moment of maximum contraction of the pump segment chamber, the stage of exfusion starts. |
|
Invention refers to immunology, transfusion medicine and intensive therapy, and may be used to treat endotoxemias of various aethiologies. That is ensured by blood sampling, centrifuging to plasma and erythrocyte-leukocyte mass. The leukocyte suspension is added with interferon inducers, hepatoprotectors and antioxidants in sub-therapeutic doses. The leukocyte suspension is incubated at t - 37°C for 120 min, and then introduced into the patient's venous bed. The erythrocyte mass is added with cerebroprotectors, hepatoprotectors and antioxidants in sub-therapeutic doses. The erythrocyte mass is incubated at t - 37°C for 45 min, and then introduced into the patient's venous bed. With no contraindications, the second session of each cycle involves the exposure to ultrasound (ultraviolet irradiation 150 J) preceding the incubation of the leukocyte suspension with the added therapeutic preparations. The length of treatment makes three 5-session cycles in average every 2 days as recommended. The length of each session is min. 3.5 hours and max. 4.5 hours. The 1st and 2nd cycles are separated by 2 weeks, while the 2nd and 3rd ones - by 4 weeks. The total therapeutic course makes 2-3 months. |
|
Method of treating patients with refractory and recurrent clinical course of hodgkin's lymphoma Invention refers to medicine, namely to oncology and hematology, and may be used in treating the patients with refractory and recurrent clinical course of Hodgkin's lymphoma. For this purpose, 24 hours before the leucopheresis procedure, a granulocyte colony-stimulating factor is administered to the patient. That is followed by the leucopheresis procedure with using MCS "Haemonetics" blood separator, and the prepared leukapack is divided on 4 portions. The leukapack portions are collected in sterile containers and incubated for 180 minutes at temperature 37°C: portions 1 and 3 with recombinant interleukin-2 5 thousand IU/ml, portions 2 and 4 with interferon-α-2b 10 thousand IU/ml. That is followed by the intravenous, drop-by-drop reinfusions of the leukapack before a course of the polychemotherapy: portions 1 and 2 on the day of the leucopheresis procedure, portions 3 and 4 of the laukapack are kept in a fridge at temperature 0 to 8°C for 24 hours and then incubated with immune preparations in the specified mode and administered to the patient. After the course of the polychemotherapy has been completed, the leucopheresis procedure is conducted again. The above therapy is prescribed for cycles 4 and 6 of the polychemotherapy used for refractory Hodgkin lymphoma and for cycles 2 and 4 cycles of the polychemotherapy used for recurrent Hodgkin's lymphoma, regardless of a response to therapy. |
|
|
Blood container system and cassette Invention refers to medicine. A container system comprises: a first bag for whole blood or blood component reservation, a filter having a filter medium for removing the specified cells from the blood component obtained by centrifuging a fluid contained in the first bag; the second bag for blood component reservation obtained after removing the specified cells by the filter. The first tube is used to connect the first bag to a filter inlet. The second one is used to connect the second bag with a filter outlet. A blood cassette has a plate section for holding a part of the first tube and a part of the second tube and comprises a fastening to retain the filter, and a hinge section with is used to couple the fastening with the plate section to be inclined. What is disclosed is the blood cassette and method for blood processing with using the container system. |
|
Method of treating patients with craniocerebral injury with underlying acute hypertension syndrome Invention refers to medicine, namely neurosurgery and efferent therapy, and may be used in treating patients with a craniocerebral injury with underlying acute hypertension syndrome. That is ensured by blood sampling from a patient with erythrocyte 50 ml recovered. Erythrocytes are enriched with dexamethasone 1 ml and injected into the patient's blood circulatory system. The procedure is performed once a day every 2-3 days. The therapeutic course is 5 procedures. |
|
|
Method for prevention of postoperative complications following oral bone tissue surgery Invention refers to medicine, namely surgical dentistry and physiotherapy, and may be used in dental implantology for preventing postoperative infectious-inflammatory complications following bone tissue surgeries. For this purpose, the surgical intervention is followed by blood sampling from an incisional wound to be treated with ozonised gas of the ozone concentration of 20±2 mg/l. Then blood is mixed with a bone autograft and treated with ozonised gas of the ozone concentration of 20±2 mg/l. The prepared autograft is introduced into an implantation and sinus lifting site. From the second postoperative day, the incisional field is exposed to extremely high frequency for 3-6 days for 10-20 minutes. For 5-7 days, the incisional field is treated with ozonised distillate of the ozone concentration of 1-2 mg/l. |
|
|
Method of treating stomach cancer Invention refers to medicine, namely to oncology, and may be used in integrated treatment of stomach cancer. That is ensured by pre-operative blood sampling 300 ml followed by preparing autoplasma by centrifugation. All recovered autoplasma and chemopreparations are placed into a first flask; the remained blood corpuscles and chemopreparations are placed into a second flask. The flasks are separately incubated for 40 minutes at 37°C. A colonic surgery follows. The surgery begins with the drop-by-drop intravenous introduction of the incubated blood corpuscles and chemopreparations from the second flasks. Upon completion of the surgery, before closure of an abdominal wall, drain tubes are blocked; the abdominal cavity is processed with autoplasma and chemopreparations from the first flask, and autoplasma and chemopreparations are kept in the abdominal cavity. The abdominal wall is closed. Then 3 hours upon completion of the operation, the drain tubes are opened. |
|
|
Method of treating colonic liver metastases Invention refers to medicine, namely oncology, and may be used in integrated treatment of liver metastases of colon cancer. That is ensured by pre-operative blood sampling 200 ml followed by preparing autothrombotic mass by centrifugation. Autothrombotic mass 5 ml and chemopreparations are placed into a first flask; the remained blood corpuscles, plasma and chemopreparations are placed into a second flask. The flasks are separately incubated for 40 minutes at 37°C. A colonic laparoscopic operation follows. The operation begins with the drop-by-drop intravenous introduction of the incubated blood corpuscles and chemopreparations from the second flask. It is followed by laparoscopic extraction of liver metastases; thereafter incubated autothrombotic mass with chemopreparations from the first flask are introduced through a laparoscopic puncture needle into a bed of the extracted metastasis. |
|
|
Invention refers to medicine, namely efferent therapy, neurology and neurosurgery, and may be used in treating patients with a craniocerebral injury with underlying hypertension syndrome during rehabilitation. That is ensured by blood sampling from a patient with erythrocyte 50 ml recovered. Then erythrocytes are saturated with nootropil 3 ml and injected back into the patient's blood-vascular system. The procedure is performed once a day every 2-3 days. The therapeutic course is 5 procedures. |
|
|
Method of treating stomach and colonic liver metastases Invention refers to medicine, namely oncology, and may be used in integrated treatment of liver metastases of stomach and colon cancer. That is ensured by pre-operative blood sampling 200 ml followed by preparing autoplasma by centrifugation. Autoplasma 5 ml and chemopreparations are placed into a first flask; the remained blood corpuscles, plasma and chemopreparations are placed into a second flask. The flasks are separately incubated for 40 minutes at 37°C. A colonic surgery follows. The surgery begins with the drop-by-drop intravenous introduction of the incubated blood corpuscles and chemopreparations from the second flasks. It is followed by ultrasound-aided radio frequency thermal ablation of liver metastases. Upon completion, incubated autoplasma and chemopreparations from the first flask are introduced through an infusion pump in an electric surgical device in a bed of thermally destructed metastasis. |
|
|
Method of adjuvant therapy of stomach cancer Invention refers to medicine, namely to oncology, and may be used in integrated treatment of stomach cancer. That is ensured by a surgical intervention to place a microirrigator into an abdominal cavity. Then 4 weeks after the surgery, blood 300 ml is taken on the first day to be centrifuged and to recover autoplasma. Autoplasma and chemopreparations are placed into a first flask, autoplasma - into second and third flasks, blood corpuscles and chemopreparations - into a forth force. The 2nd and 3rd flasks are frozen, the 1st and 4th flasks are separately incubated for 40 minutes at 37°C. The incubated blood corpuscles and chemopreparations from the 4th flask are introduced intravenously drop-by-drop. Autoplasma and chemopreparations from the 1st flask are introduced intraperitoneally through the microirrigator. It is followed by 1 session of radiation therapy on the abdominal cavity at single dose 2 Gy. On the 2nd and 4th therapeutic days, only sessions of radiation therapy are applied. On the 3rd and 5th days, the sessions of radiation therapy are preceded by freezing one flask with autoplasma added with chemopreparations, and the flasks are incubated for 40 minutes at 37°C. Then autoplasma and chemopreparations are introduced intraperitoneally through the microirrgator, and the session of radiation therapy is conducted. On the 6th and 7th days, a pause is made. Starting from 8th and 15th days, a five-day therapeutic course is repeated. |
|
|
Method for integrated treatment of acute thromboembolia of pulmonary artery Invention refers to medicine, namely angiology, intensive care, cardiovascular surgery and phlebology, and may be used for integrated treatment of acute thromboembolia of pulmonary artery. That is ensured by prescribing anticoagulants, disaggregants, antibiotic therapy added by thrombolytic therapy by the oral introduction of the preparation Thrombovasim 0.02 mg/kg combined with deobliteration of pulmonary artery or pulmonary trunk by direct surgical thromboembolectomy in complete bypass with retrograde perfusion of pulmonary arteries. Treatment of acute thromboembolia is added by prescribing the preparation Vasaprostan* 60 mcg daily intravenously starting from the moment of diagnosing and up to 7 postoperative days. |
|
|
Method of treating large intestine cancer metastases into liver Invention relates to medicine, namely, to oncology, and can be used in complex treatment of metastases in liver, in particular of large intestine cancer. For this purpose, performed is sampling of 200 ml of blood with its further centrifuging and separation of autoleukomass. 5 ml of autoleukomass and chemical preparations are placed into the first vial, the remaining formed elements of blood, plasma and chemical preparations are placed into the second vial. Vials are incubated separately for 40 minutes at 37°C. After that transcutaneous radio-frequency thermal ablation of metastases into liver is performed under ultrasound control. When thermal ablation is finished, incubated autoleukomass with chemical preparations from the first vial is introduced into the bed of metastasis subjected to thermal destruction by means of infusion pump in electrosurgical device. Simultaneously incubated formed elements of blood, plasma with chemical preparations from the second vial are introduced intravenously by drop infusion. |
|
|
Method for assessing clinical effectiveness in prostate cancer Invention refers to medicine, namely oncology, and may be used in treating patients with generalised prostate cancer. That is ensured by androgen blockade. Three days later, AMACR, bcl-2, bmp-7 protein levels are measured by laser disorption time-of-flight mass spectrometry. It is followed by the intravenous introduction of the mixture of autoblood 150 ml and docetaxel 80 mg incubated at 37°C for 40 minutes. In 21 days, the same amount of said mixture is introduced to total amount of docetaxel 400 mg. Five introductions of the chemopreparations are prescribed. The protein levels are measured once again. Decreasing the levels in 3-5 times testifies to the clinical effectiveness, while decreasing the protein levels less than in 3 times shows no therapeutic effect. |
|
|
Method of preoperative autoblood banking in cardiosurgical patients Invention refers to medicine, specifically cardiosurgery, and may be used in open heart surgery. For this purpose, 2 days before the surgery the intensity of an anaerobic threshold is determined by inhaling a hypoxic gas mixture during ergospirometry. The breathing process is accompanied with stepped decrease of the oxygen content in the mixture by 2% to achieve oxygen consumption and carbon dioxide release at each stage of stabilisation. If the intensity of the anaerobic threshold is more than 14% of oxygen, a degree of patient's cardiorespiratory adaptation is considered to be low, and autoblood is sampled in the amount of max. 5% of circulating blood. If the intensity of the anaerobic threshold is 10-14% of oxygen, a degree of patient's cardiorespiratory adaptation is considered to be moderate, and autoblood is sampled in the amount of max. 7% of circulating blood. If the intensity of the anaerobic threshold is less than 10% of oxygen, a degree of patient's cardiorespiratory adaptation is considered to be high, and autoblood is sampled in the amount of max. 10% of circulating blood. |
|
|
Disposable extracorporeal circulation and extracorporeal blood treatment apparatus Group of inventions refers to medicine. A cartridge unit comprises a rigid body, a first flexible tube with its first and second ends attached to the rigid body forming a loop part wherein there is a hose pump rotor of a medical device with the first end of the first flexible tube connected to an outlet of a first chamber, a second flexible tube with its first end connected to an inlet of a first chamber, a third flexible tube with its first end attached to the rigid body and being in a liquid connection with a second end of the first tube. A rigid tubular part comprises first and second terminal connector and an intermediate portion passing between the connectors contacting with a fluid medium flowing through the intermediate portion for the purpose of measuring a fluid medium parameter. The first terminal connector is attached to one element chosen from a group consisting of: the second end of the second flexible tube, and the second end of the third flexible tube. The connectors have an external prismatic surface having radially projecting element coupled with a connective socket on a holder of the apparatus. There are disclosed versions of the cartridge unit, the rigid tubular part and a medical apparatus applying them. |
|
Method of complex purification of physiological fluids Invention relates to efferent medicine and can be used in case of necessity of extracorporal blood purification in patients with purulent-septic conditions. For this purpose perfusion of blood through column with sorbent is performed. As sorbent Strosorb 414, or stirosorb 514, or Stirosorb 516 is used. |
|
Method of complex treatment of pilonidal cyst Invention relates to medicine, namely to coloproctology and deals with treatment of pilonidal cyst. Method includes excision of pilonidal cyst, bringing wound edges to wound bottom and partial suturing of wound with single "П"-shaped sutures without tension, carrying out antibiotic therapy. Before bringing wound edges to wound bottom on its lateral surface from the side of subcutaneous adipose cellular tissue made are 0.5 cm deep linear cuts along entire wound length at the distance 0.5 cm from the skin surface. At the distance 1.0-1.5 cm from post-operative wound edges at the level of wound bottom symmetrically from two sides installed are polychlorvinyl tubes equal in length to the wound length, with holes on the lateral surface, located in each 2 cm. In order to carry out immunotherapy, patient's blood is sampled, its cell masses are separated by centrifugation. Erythrocyte mass is returned to patient. Remaining cell mass is cultivated with 500000 U of interleukin-2 for 60 minutes at temperature 37°C, centrifuged with separation of supernatant fluid. Supernatant fluid, which contains complex of autologous cytokines, is introduced through tubes in volume 5 ml per each 2 cm of wound length on the first and third day after operation. |
|
Method for ultraviolet irradiation of platelets concentrates in flexible containers FIELD: medicine. SUBSTANCE: method includes preparation of platelets concentrates (PC) and the irradiation with ultraviolet radiation with the wavelength from 200 nm to 280 nm (UV-C radiation) with radiation energy in the range from 0.01 to 2 J/cm2. Every dose of PC is contained in flexible, UV-permeable flat package for irradiation with the volume up to 5000 ml, filled by less than 30% of maximal capacity. The package during irradiation is moved by the way of shaking, rocking, rotating, so that content is circulating and during circulation the zones with variable thickness of layers is formed. Additionally the irradiation with UV-B radiation with radiation energy in the range from 0.3 to 5 J/cm2 is performed. The plasma content in PC is more than 20% w/w. EFFECT: pathogenic microbes and leucocytes deactivation while the platelet function remains unaltered. 25 cl, 8 tbl, 8 ex |
|
|
Method of treating soft tissue sarcomas Invention relates to medicine, namely to oncology and can be used in treatment of soft tissue sarcomas as one of complex treatment components. For this purpose sampling of 400 ml of blood into vial with hemopreservative is carried out with its further centrifugation at 1500 rotations per minute during 30 minutes. After that, plasma is divided into two equal parts into sterile vials: into one of them introduced are 600 mg/m2 of cyclophpsphane, into the other - methotrexate 40 mg/m2, and blood cells are connected with doxorubicin - 40 mg/m2. All mixtures are incubated for 30 minutes at 37°C. After that on the first and seventh day of treatment intravenously simultaneously introduced are blood cells with doxorubicin and mixtures of autoplasm with cyclophosphane and then with methotrexane are injected around tumour on its circumference. |
|
|
Medical apparatus for extracorporal blood purification Invention relates to medicine and is applied for extracorporal blood purification. Device for blood purification is made with possibility of connection to patient's blood circulation through extracorporal mains and contains at least one blood pump, control unit for control of blood pump and for control of work modes, and chamber, made with possibility of pointing at place of treatment. Chamber is chamber of colour image, which is connected with recognising device for recognising blood colour and size of occupied by blood area of image. Described is method of control over work of medical apparatus for extracorporal blood purification, in which applied is chamber of colour image, which is connected with recognising device for recognising blood colour. On the basis of colour signals determined is size of occupied by blood image surface. |
|
Non-contact measurement of flow parameters Invention relates to medical equipment, namely to ultrasound sensors of flow, used in surgical systems. Elastomeric acoustic connector contains body, rim, surrounding perimeter of said body, which has internal edge, and protruding central site, located in the centre of body. Protruding central site has upper edge, lower edge and semi-cylindrical shape. Connector is also provided with partition, which connects site with rim and loop, extending from body. Protruding central site protrudes above partition level, its upper and lower edges being collinear to internal edge of rim. In addition protruding central site has section which extends in said loop. Surgical cassette contains case, valve plate, connected with one side of case and having made in it hollow, cover, connected with opposite side of case and window of transfer, located in hollow. Canal of fluid is formed in valve plate and case, acoustic connector is formed in hollow on transfer window. Surgical system contains surgical consol with site for cassette reception, ultrasound converter, located on said site and made with possibility of measuring fluid flow parameters. Acoustic connector is fixed to cassette. |
|
Method of hemosorption in small laboratory animals Invention refers to medicine, namely to an efferent therapy and experimental medicine, and can be used if detoxification required by hemosorption. That is ensured by femoral vessel catheterisation in small laboratory animals by needle vessel puncture, and sequential introduction of a plastic conductor and a plastic catheter. Ends of the plastic catheter are delivered on an animal's back within lumbar vertebrae through a tunnel formed by a blunt dissection between a femoral bone and group of femoral adductors. Then the catheter ends are coupled with matched unions of a microcolumn. |
|
|
Method for selective removal of component from aqueous liquid Invention relates to a method for selective binding and extraction of at least one component from whole blood or humour, where the blood or humour is allowed to pass through a hard integrated separating matrix without leaking from it. The matrix has a porous structure with pore size ranging from 5 mcm to 500 mcm, as well as an active surface whose area ranges from 0.5 cm2 to 10 m2, and this surface is cable of binding such components. |
|
Method of treating liver abscess in children Invention relates to medicine, namely to abdominal surgery, hepatology and methods of detoxication, and can be applied for treatment of liver abscess of different etiology. For this purpose after sanitisation of purulent nidus cavity of liver abscess is processed with 0.25% solution of derinate, then blood sampling is carried out in quantity 150-200 ml of blood, after centrifugation of which erythrocytes are returned to patient, and leucocytes are extra-corporeally processed with 0.5% solution of glutoxim in dose 1 ml and diluted in 50-100 ml of 0.9% solution of NaCl with following intravenous drop introduction, and from the following day into cavity introduced is 0.25% solution of derinate in dose 1.5 ml one time per day during 5 days. |
|
|
Method of treating purulent wounds of soft tissues Invention relates to medicine, namely to purulent surgery, and can be used in treatment of patients with purulent wounds of soft tissues. For this purpose antibacterial and immune therapy are carried out. Immunotherapy is performed in the following way. Blood is sampled from patient, by plasmapheresis leukocyte cell mass is obtained from it and cultivated with 1 000 000 Units of interleukin -2 and 200 ml of NaCl 0.9% solution for 60 min at temperature 37°C, with further centrifugation. After that, obtained complex of cytokins is introduced uniformly subcutaneously symmetrically at distance 1.0 cm from wound edges until infiltration bank in volume 10-80 ml with 10 ml of solution per each 5 cm of wound length is created. Introduction is performed on the 1-st, 3-rd and 5-th day of post-operative period. |
|
|
Method of treating prostate cancer Invention relates to medicine, in particular to oncology, and can be used for reduction of pain syndrome in prostate cancer. For this purpose catheter is installed into subarachnoid space between the fourth and fifth lumbar vertebrae; 5 ml of cerebrospinal fluid are sampled, mixed with suspension of 125 mg of hydrocortisone, mixture is incubated in thermostat for 30 minutes at temperature 37°C and introduced through the installed catheter 1 time per day with a day interval, without removing the catheter. Total number of mixture introductions is 5. |
|
|
Method of immune insufficiency correction in patients with mechanical jaundice of non-tumour genesis Invention relates to medicine, can be applied in resuscitation science, surgery, clinical immunology. For correction of immune insufficiency in patients with mechanical jaundice of non-tumour genesis in addition to complex traditional therapy of post-operational period from the first day after operation one time per day intravenously introduced is 1 ml of 1%-solution of glutoxim on autoblood, with its preliminary 30 minute incubation with 20 ml of autoblood. Treatment course is 5 sessions. |
|
Method of removal of pathologic prion protein from blood products Blood product filtration through filter, filled with carrier, covered with polymer, is performed. Said polymer is formed by three elements: element derived from hydrophobic polymerised monomer, element, derived from polymerised monomer, which contains main nitrogen-containing part, and element, derived from polymerised monomer, which contains proton neutral hydrophilic part as balance. After filtration collection of blood product is carried out. Efficiency of pathologic prion protein removal constitutes from 1.2 to 4.1 and higher. |
|
Method of obtaining autogenic activated platelet-enriched plasma for dentistry Sampling of blood from patient's ulnar vein with first and second syringe-test-tubes is carried out. First syringe-test-tube is centrifuged with acceleration 250 g for 10 minutes. Formed plasma and coagulated blood in second syringe-test-tube are centrifuged with acceleration 1000 g for 10 minutes. Platelet-poor plasma is separated from platelet-enriched plasma. Activator of platelet-enriched plasma is prepared from supernatant fluid after centrifugation of coagulated blood and platelet-poor plasma, with weight ratio in fractions: 1:1, and 10% calcium chloride solution. The latter - in drop manner, mixing until required mixture concentration is obtained. Platelet-enriched plasma is mixed with activator with weight ratio in fractions 1:3 respectively. |
|
|
System includes a kit of disposable elements for transportation of liquid, which are preliminarily connected or include aseptic connectors for creation of connections between them in aseptic way, or are adapted for being aseptically connected. Kit includes three sets of disposable sterile elements: set for collection, set for processing and set for transplantation, packed in blister packing on carrier, such as tray, which has one department, containing each connected with other set of said kit. System can be applied for obtaining platelet concentrate for separate application. Method of collection and processing of cell subpopulation includes collection of isolated cells in collection chamber, connected with isolation device, processing of cells in centrifugal operation chamber, which is the same chamber as the chamber for collection, or which is connected with collection chamber, and collection of processed cells in chamber for reinfusion, which also is the same chamber as the operation chamber, or which is connected with operation chamber, and delivery of processed cell subpopulations back to the patient. |
|
Method of treating secondary lymphedema of upper extremities Invention refers to medicine, namely to surgery, and can be used in treating patients with secondary lymphedema of upper extremities. That is ensured by the introduction of autolymphocytes extracorporally processed with Roncoleukin and dissolved in normal saline in subcutaneous fat of an injured extremity in a projection of lymph node basins along a medial and lateral surface of forearm. The solution is introduced in 20 points by 0.5 ml containing 20 to 30 million cells per each point on the average. The procedures are thrice-repeated every 72 hours. |
|
|
Method involves the intravenous and/or intramuscular introduction of the drugs used in myelopathy, balneotherapy in the form of baths. Acupressure and manual therapy are applied in addition. The manual therapy requires such techniques, as ischemic compression, release phenomenon, fascial broach, postisometric relaxation of the muscles involved in a pathological process. Discontinuous therapeutic plasmapheresis is applied with using either Baxter, or Bekman, or Haemophoenix apparatuses, and/or extracorporal ultraviolet blood irradiations is ensured by the apparatus Isolda MD 73 M. The apparatus Cryo-Jet is used for cryotherapy with cooled dry air at the level of degenerative dystrophic changed vertebral motor cervical segments and muscle attachment points. |
|
|
Method of treating malignant lung neoplasms in experiment Invention relates to medicine, oncology, and can be used for treatment of malignant lung neoplasms in experiment. For this purpose performed is extracorporal irradiation of autoblood with red incoherent light λ=0.67 mcm dose W=3.06 J/cm2 in continuous mode with exposition duration to three minutes. After that 15-20 minutes later into said blood added is cyclophosphane in dose 40 mg/kg and the mixture is incubated for 40 minutes at T=37°C. After that it is re-infused into subclavian vein of the animal. |
|
|
Method of intergrated treatment of tuboperitoneal infertility Invention refers to medicine, namely to gynecology and concerns the integrated treatment of tuboperitoneal infertility. That is ensured by low-intensity infrared lasing at power 150 Wt, wave length 0.89 mcm of the inguinal lymph nodes and a skin projection of the lumbosacral plexus. The exposure time is 1 min for each region for 1st session. Thereafter, the exposure time is increased to 3 minutes during 10 sessions. It is combined with local intraendometrial introduction of an antibacterial agent and an immunomodulator. Besides the treatment involves a number of plasmapheresis sessions and introduction of nonsteroidal anti-inflammatory drugs, antioxidants, desensitisers, and vaginal sanitation. |
|
|
Method for body detoxification in critical endotoxicoses Invention refers to medicine, namely to surgery and intensive therapy, and can be used in treating endotoxicoses caused by septic conditions. That is ensured by removal of a destruction area to be thereafter sanitised and drained. It is followed with lymphostimulating therapy by introduction of 0.25% Novocaine 60 ml with dissolved 0.1 g of Lydase and 1.0 ml of Pentoxifylline into the interspinous spaces in number of 1-3 injections. Further, discrete plasmapheresis in amount 400 ml for severe patients and 800 ml in moderate patients is applied in number of 1-8 procedures. The lymphostimulating therapy is alternated every second day with lymphotropic extracorporal pharmacoimmunotherapy with using a medicated mixture prepared by incubation of 40-60 ml of the patient's plasma with received plasma of the patient with Roncoleukin in dosage 500-1 million UN and Cefabol in dosage 1 g for 45 min at 37°C. In peritonitis and peritoneal sepsis, the medicated mixture is introduced in the bolus form in the retroperitoneal fat. The destructive processes in the pleural cavity require introduction of said mixture in the axillary cavity. |
|
|
Invention relates to medicine, namely to dermatology, and can be used for treating patients with psoriasis. Method includes drug therapy with application of hyposensibilising anti-histamine medications, hepatoprotectors, vitamins, local exfoliating and releasing ointments, general ultraviolet oirradiation. Method also includes plasmapheresis with division of blood into plasma and erythrocyte mass by centrifugation with removal of patient's plasma and erythrocyte mass reinfusion. Before returning erythrocyte mass into patient's organism it is processed with 200 ml of ozonised physiological solution with ozone concentration 2.5 mg/l. After that reinfusion of ozonised erythrocyte mass is carried out. |
|
|
Method of treating anemia in chemoradiation therapies Invention refers to medicine, namely to oncology, and can be used in contraction of anaemia accompanying the chemoradiation therapy. That is ensured by blood exfusion in amount 8-10% of the circulating blood volume, and the removed blood volume is replaced with crystalloids in the ratio 1:1. From the exfused blood, erythrocyte concentrate is recovered whereto Essentsiale N solution 5 ml is added; the prepared mixture is placed in a thermostat at temperature 37°C for 10 minutes. Then 100 ml of a physiologic saline is added to said mixture that is rocked. The prepared solution is introduced to the patient within 20 minutes with a simultaneous UV blood irradiation. Exfusion and extracorporal blood processing combined with UV irradiation are performed every second day, 2-3 sessions for the therapeutic course. |
Another patent 2551229.